

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Strous et al.

Serial No.: 09/660,302

Filed: September 12, 2000

For: CONTROLLING AVAILABILITY OR
ACTIVITY OF PROTEINS BY USE OF
PROTEASE INHIBITORS OR RECEPTOR

Confirmation No.: 6944

Examiner: T. McKelvey

Group Art Unit: 1636

Attorney Docket No.: 2183-4525US

NOTICE OF EXPRESS MAILING


Express Mail Mailing Label Number: EV326919862US

Date of Deposit with USPS: March 26, 2004

Person making Deposit: Christopher Haugh

DATE:

DISK TOXENIC



STATEMENT UNDER 37 C.F.R. §§ 1.821 THROUGH 1.825

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Andrew F. Nilles, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:


1. The enclosed paper copy of the substitute SEQUENCE LISTING, as well as the enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF), are included herewith to comply with the requirements of 37 C.F.R. §§ 1.821 and/or 1.825 as requested by the Examiner.

Serial No.: 09/660,302

2. The enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF) is believed to be the same as the paper copy of the substitute SEQUENCE LISTING.

3. The SEQUENCE LISTINGS submitted herewith are believed to contain no "new matter" with regard to the referenced patent application.

Respectfully submitted,



Andrew F. Nilles
Registration No. 47,825
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: March 23, 2004

AFN/bv

Document in ProLaw